Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.

about

Inhibitory Effects of a Novel PPAR-γ Agonist MEKT1 on Pomc Expression/ACTH Secretion in AtT20 Cells.

P2860

Q55423757-09D6F002-3BF0-470C-95E9-BA46354F2CF9

P2860

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.

Item

http://www.wikidata.org/entity/Q46624867

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.

@en

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.

@nl

type

Item

label

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.

@en

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.

@nl

prefLabel

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.

@en

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.

@nl

P1476

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis

@en

P2093

Katya Uzunova

http://www.w3.org/2001/XMLSchema#string

Krassimir Kalinov

http://www.w3.org/2001/XMLSchema#string

Toni Vekov

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Thiazolidinediones: a 2010 perspective.

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

Correlation between cardiovascular disease and diabetes mellitus: current concepts.

Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes

New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications.

P2888

s13098-017-0290-5

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13098-017-0290-5

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elena Filipova

P577

2017-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092688554

http://www.w3.org/2001/XMLSchema#string

P698

29163673

http://www.w3.org/2001/XMLSchema#string

P932

5686837

http://www.w3.org/2001/XMLSchema#string

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.

about

P2860

P2860

Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P6179

P698

P932